Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$1.2 million.

  • Lyell Immunopharma's Change in Accured Expenses fell 81.51% to $572,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year decrease of 695.39%. This contributed to the annual value of -$1.2 million for FY2024, which is 73.85% down from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Change in Accured Expenses is -$1.2 million, which was down 73.85% from -$719,000 recorded in FY2023.
  • Lyell Immunopharma's Change in Accured Expenses' 5-year high stood at $6.1 million during FY2020, with a 5-year trough of -$1.2 million in FY2024.
  • In the last 3 years, Lyell Immunopharma's Change in Accured Expenses had a median value of -$719,000 in 2023 and averaged -$810,667.
  • Data for Lyell Immunopharma's Change in Accured Expenses shows a maximum YoY plummeted of 110.19% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Lyell Immunopharma's Change in Accured Expenses stood at $6.1 million in 2020, then fell by 25.78% to $4.5 million in 2021, then tumbled by 110.19% to -$463,000 in 2022, then slumped by 55.29% to -$719,000 in 2023, then tumbled by 73.85% to -$1.2 million in 2024.